By leveraging a precision medicine strategy based on biomarkers and clinical data, we maximize the success rate of drug development to solve the unmet medical needs of hematologic cancers and chronic diseases.
NOBO-VERSE
(Proprietary Platform)
| Hemato-Malignancy | Project | Discovery | Preclinical | Phase Ⅰ | Phase Ⅱ | Phase Ⅲ | Approved |
|---|---|---|---|---|---|---|---|
| Project 202 (R/R PCNSL) |
|
||||||
| Project 201 (R/R DLBCL) |
|
||||||
| Project 204 (R/R DLBCL) |
|
||||||
| Project 205 (R/R SCNSL) |
|
||||||
| Project 203 (R/R MZBCL) |
|
||||||
| Hemato-Inflammation | Project 101 |
|
|||||
| Project 301 |
|
||||||
| Project 501 |
|
||||||